M1 Ltd. Aktie
Finanztrends
Deine Einschätzung
Was spricht für und gegen M1 Ltd. in den nächsten Jahren?
Pro
?
M****
?
M************
?
A****************
Kontra
?
W******* i* V********
?
U****************
?
L*********** I********** f** d** n******* J****
Sag uns deine Meinung, um die 'Wisdom of the Crowds' zu nutzen
Rendite von M1 Ltd. im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| M1 Ltd. | - | - | - | - | - | - | - |
| Spok Holdings Inc. | 0,51 % | 2,67 % | 4,35 % | -38,06 % | -12,57 % | -26,15 % | 45,45 % |
| Apt Satellite Hldgs | 0,00 % | 0,00 % | 0,00 % | -8,65 % | -24,00 % | -25,20 % | -18,80 % |
| SmarTone Telecommunications Holdings Ltd | -0,94 % | -0,93 % | 1,92 % | 3,92 % | 7,29 % | -0,93 % | 16,74 % |
News
Contineum Therapeutics Touts PIPE-791 IPF Focus as Pain Data Hint at Wider Potential
Key Points
- Interested in Contineum Therapeutics, Inc.? Here are five stocks we like better.
- Contineum remains focused on PIPE-791 for idiopathic pulmonary fibrosis (IPF), saying the drug’s
IRSA Inversiones Y Representaciones Q3 Earnings Call Highlights
IRSA Inversiones Y Representaciones (NYSE:IRS) reported a sharply higher net result for the first nine months of fiscal 2026, supported by stronger performance across its rental businesses and